People with advanced dementia can receive poorer quality end of life care compared to those with conditions such as cancer. People with dementia have less access to palliative care and are less likely to die in their preferred place of care and may experience unnecessary hospital admissions in the last year of life.

The supporting Excellence in End of Life Care for people with Dementia (SEED) project is a five year project designed to develop and test an intervention to support professionals to deliver good quality, community-based end of life care for people with dementia.

This presentation will detail two studies within this project. The first is a Q methodology study designed to identify the features of end of life care that are important to people with dementia and their carerssss to inform the SEED intervention. The second is a contingent valuation study to elicit the monetary value of the SEED intervention for use in a Cost Benefit Analysis.

Helen Mason is a Professor of Health Economics at Glasgow Caledonian University working in the area of economic evaluation with a specialist interest in the development and use of methodologies to elicit patient and public preferences for health care. Helen has a MSc in Health Economics from the University of York and in 2007 she was awaded a PhD from Newcastle University in which she developed methods to estimate the monetary vaule of QALYs. Helen leads the economic evaluation components of clinical trials worth over £10 million across a range of clinical areas such as Dementia, Stroke, Multiple Sclerosis, Prolapse and Musculoskeletal Conditions.